JPH11511962A5 - - Google Patents

Info

Publication number
JPH11511962A5
JPH11511962A5 JP1997501337A JP50133797A JPH11511962A5 JP H11511962 A5 JPH11511962 A5 JP H11511962A5 JP 1997501337 A JP1997501337 A JP 1997501337A JP 50133797 A JP50133797 A JP 50133797A JP H11511962 A5 JPH11511962 A5 JP H11511962A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1997501337A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11511962A (ja
Filing date
Publication date
Priority claimed from US08/478,121 external-priority patent/US5620846A/en
Priority claimed from US08/618,485 external-priority patent/US6410269B1/en
Application filed filed Critical
Publication of JPH11511962A publication Critical patent/JPH11511962A/ja
Publication of JPH11511962A5 publication Critical patent/JPH11511962A5/ja
Ceased legal-status Critical Current

Links

JP9501337A 1995-06-07 1996-06-05 クローン化したビタミンd結合タンパク質由来の大食細胞活性化因子 Ceased JPH11511962A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/478,121 US5620846A (en) 1995-06-07 1995-06-07 Diagnostic and prognostic indices for cancer and aids
US08/478,121 1995-06-07
US08/618,485 1996-03-19
US08/618,485 US6410269B1 (en) 1995-06-07 1996-03-19 Preparation of potent macrophage activating factors derived from cloned vitamin D binding protein and its domain and their therapeutic usage for cancer, HIV-infection and osteopetrosis
PCT/US1996/008867 WO1996040903A1 (en) 1995-06-07 1996-06-05 Macrophage activating factors derived from cloned vitamin d binding protein

Publications (2)

Publication Number Publication Date
JPH11511962A JPH11511962A (ja) 1999-10-19
JPH11511962A5 true JPH11511962A5 (enExample) 2004-07-22

Family

ID=27045792

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9501337A Ceased JPH11511962A (ja) 1995-06-07 1996-06-05 クローン化したビタミンd結合タンパク質由来の大食細胞活性化因子

Country Status (12)

Country Link
US (3) US6410269B1 (enExample)
EP (3) EP1340815A3 (enExample)
JP (1) JPH11511962A (enExample)
CN (2) CN1174097C (enExample)
AT (1) ATE307885T1 (enExample)
AU (1) AU6253596A (enExample)
BR (1) BR9609072A (enExample)
CA (1) CA2223940A1 (enExample)
DE (2) DE69635346D1 (enExample)
ES (1) ES2252756T3 (enExample)
NO (1) NO323155B1 (enExample)
WO (1) WO1996040903A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985545A (en) * 1996-03-19 1999-11-16 Yamamoto; Nobuto Diagnostic and prognostic ELISA assays of serum α-N-acetylgalactosaminidase for AIDS
CA2409759A1 (en) * 2000-05-09 2001-11-15 Children's Medical Center Corporation Method and composition for the treatment of angiogenesis
WO2002021133A2 (en) * 2000-09-07 2002-03-14 The Brigham And Women's Hospital, Inc. Methods of detecting cancer based on prostasin
US20050009120A1 (en) * 2000-09-07 2005-01-13 The Brigham And Women's Hospital, Inc. Methods of detecting ovarian cancer based on osteopontin
WO2002058589A2 (en) * 2000-11-09 2002-08-01 Northeastern Ohio Universities College Of Medicine Agents and methods for promoting bone growth
US20020164664A1 (en) * 2000-11-30 2002-11-07 Matritech, Inc. Detection and treatment of prostate cancer
US7112408B2 (en) * 2001-06-08 2006-09-26 The Brigham And Women's Hospital, Inc. Detection of ovarian cancer based upon alpha-haptoglobin levels
US6806355B2 (en) 2001-08-14 2004-10-19 Statens Serum Institut Purification process for large scale production of Gc-globulin, the Gc-globulin produced hereby, a use of Gc.globulin and a Gc-globulin medicinal product
US7288383B2 (en) * 2003-01-15 2007-10-30 The Brigham And Women's Hospital, Inc. Eosinophil-derived neurotoxin as a marker for ovarian cancer
WO2005087793A2 (en) * 2004-02-05 2005-09-22 The Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Immunostimulatory compositions and uses thereof
US20050186577A1 (en) * 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
WO2006063028A2 (en) * 2004-12-07 2006-06-15 The Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Immunostimulatory compositions and uses thereof
US8496942B2 (en) 2006-12-13 2013-07-30 Susavion Biosciences, Inc. Therapeutic peptides and uses thereof
US8460697B2 (en) 2006-12-13 2013-06-11 Susavion Biosciences, Inc. Pro-angiogenic peptides and uses thereof
USRE46425E1 (en) 2006-12-13 2017-06-06 Susavion Biosciences, Inc. Pro-angiogenic peptides and uses thereof
US7811995B2 (en) 2006-12-13 2010-10-12 Susavion Biosciences, Inc. Therapeutic and diagnostic peptides
US7838497B2 (en) 2006-12-13 2010-11-23 Susavion Biosciences, Inc. Pro-angiogenic peptides
IN2012DN02200A (enExample) * 2009-08-22 2015-08-21 Charles Knezevich
EP2612921B1 (en) 2010-09-03 2016-11-02 Morita Pharmaceutical Ind., Ltd. Method for production of novel degalactosylated gc globulin
CN103547280B (zh) * 2011-04-07 2017-06-09 艾弗兰纳特有限公司 用于药物组合物的巨噬细胞活化因子
EP2561879A1 (en) 2011-08-23 2013-02-27 Protea Biopharma N.V. Macrophage activating factor for use in the treatment of chronic fatigue syndrome (CFS) and CFS-related diseases and disorders
WO2013130953A2 (en) * 2012-03-01 2013-09-06 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
EP2687264A1 (en) 2012-07-17 2014-01-22 Protea Biopharma N.V. Macrophage Activating Factor for treatment of endometriosis
WO2014113641A1 (en) * 2013-01-18 2014-07-24 Kline Ellis Selective glycosidase regimen for immune programming and treatment of cancer
CN105530950A (zh) * 2013-06-09 2016-04-27 艾弗兰纳特有限公司 包含Gc-巨噬细胞活化因子的组合物及其用途
AT518622A1 (de) * 2016-04-21 2017-11-15 Hg Pharma Gmbh Dimerer Komplex aus selektiv deglycosyliertem Vitamin D bindenden Protein (GcMAF) und Cholecalciferol (Calciol) und Verfahren zu dessen Herstellung
EP3725883B1 (en) * 2017-12-15 2024-01-24 Foundation for Biomedical Research and Innovation at Kobe Method for producing active gcmaf
JPWO2022124331A1 (enExample) 2020-12-08 2022-06-16
CN118325844B (zh) * 2023-09-07 2025-01-03 武汉奥科博泰生物科技有限公司 识别N-乙酰-β-D-氨基葡萄糖苷酶的单克隆抗体及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326749A (en) 1989-11-20 1994-07-05 Nobuto Yamamoto Macrophage activating factor from vitamin D binding protein
US5177002A (en) * 1989-11-20 1993-01-05 Nobuto Yamamoto In vitro enzymatic conversion of glycosylated human vitamin D binding protein to a potent macrophage activating factor
US5177001A (en) 1989-11-20 1993-01-05 Nobuto Yamamoto In vitro enzymatic conversion of glycosylated mammalian vitamin D-binding protein to a potent macrophage activating factor
US5516657A (en) * 1992-05-11 1996-05-14 Cambridge Biotech Corporation Baculovirus vectors for expression of secretory and membrane-bound proteins
US5652352A (en) * 1994-03-31 1997-07-29 Amgen Inc. Afamin: a human serum albumin-like gene

Similar Documents

Publication Publication Date Title
JP2000500445A5 (enExample)
JP2000500033A5 (enExample)
JP2000500228A5 (enExample)
JP2001519643A5 (enExample)
JP2000500440A5 (enExample)
JP2000500327A5 (enExample)
JPH11508770A5 (enExample)
JP2000500145A5 (enExample)
JP2000500155A5 (enExample)
JP2000500406A5 (enExample)
JP2000500115A5 (enExample)
JP2000500322A5 (enExample)
JP2000500258A5 (enExample)
JP2000500192A5 (enExample)
JP2000500112A5 (enExample)
JP2000500226A5 (enExample)
JP2000500051A5 (enExample)
JP2000500407A5 (enExample)
JP2000500019A5 (enExample)
JP2000500166A5 (enExample)
JP2000500125A5 (enExample)
JP2000500044A5 (enExample)
JP2000500257A5 (enExample)
JP2000500090A5 (enExample)
JP2000500429A5 (enExample)